Back to Search
Start Over
5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial
- Source :
- Breast, Vol 56, Iss , Pp S21-S22 (2021)
- Publication Year :
- 2021
- Publisher :
- Elsevier, 2021.
- Subjects :
- Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Subjects
Details
- Language :
- English
- ISSN :
- 15323080 and 09609776
- Volume :
- 56
- Issue :
- S21-S22
- Database :
- Directory of Open Access Journals
- Journal :
- Breast
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.bbced2cf6847a6a447321661688820
- Document Type :
- article
- Full Text :
- https://doi.org/10.1016/S0960-9776(21)00097-7